Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Seer, Inc.NASDAQ: SEER

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $16.84M (cash outflow) fell 15.6% year over year, ahead of the -17.9% change in trailing-twelve-month net income. Sequentially, it rose 5.3% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.

Context

  • Net income amounted to 456.6% of revenue in FY2025, down 164.3 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$59.4M (-19.3%) for the fiscal year ending Dec 2026, a slowdown from the -15.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$16.84M+5.3% QoQ
Last fiscal yearDec 2025
-$73.6M-15.0% YoY
LTMMar 2026
-$70.49M-17.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.6%-22.8%-7.2 pp
1 year-15.0%-19.3%-4.3 pp
3-year CAGR-7.5%-15.1%-7.6 pp
5-year CAGR-24.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(73.6M) USD
Year-over-year change
+15.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -17.9% is the 14th highest of 19, against a peer median of +2.4%.
  • Net income amounts to 468.7% of revenue for SEER, versus a peer median of 302.7%.
SEER Competitors
Net Income for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$349.58M USD+83.2%+73.1%—
KYMRKymera Therapeutics, Inc.LTM Jun 2026$299.6M USD+8.8%+26.2%285.4%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$294.88M USD+220.5%+13.6%42.0%
LYELLyell Immunopharma, Inc.LTM Mar 2026$246.41M USD-26.3%+14.4%794858.1%
SANASana Biotechnology, Inc.LTM Mar 2026$241.99M USD+16.0%-3.2%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$221.04M USD+23.7%——
PHVSPharvaris N.V.LTM Sep 2026€179.96M EUR+11.0%+31.9%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$135.21M USD+1.8%+13.3%—
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$130.01M USD-2213.0%-29.1%302.7%
QSIQuantum-Si incorporatedLTM Mar 2026$103.82M USD+3.1%-8.5%5605.9%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$103.8M USD+0.5%-6.4%297.8%
NKTXNkarta, Inc.LTM Mar 2026$99.93M USD-10.2%-2.9%—
PEPGPepGen Inc.LTM Mar 2026$77.22M USD-24.4%+9.1%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$75.32M USD-6.4%-12.0%266.9%
SEERSeer, Inc.LTM Mar 2026$70.49M USD-17.9%-7.5%468.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 64.16M CHF+7.8%——
STTKShattuck Labs, Inc.LTM Mar 2026$49.87M USD-29.4%-21.8%4987.4%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$34.55M USD-23.8%-4.9%—
MNOVMediciNova, Inc.LTM Mar 2026$11.72M USD+5.0%-5.2%1964.3%
Peer median (excluding SEER) —+2.4%-3.1%302.7%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Depreciation & Amortization2.56M3.94M5.58M6.18M7.25M
Deferred Income Tax1.2M0000
Stock-Based Compensation25.93M33.67M34.42M28.21M15.41M
Change in Working Capital(5.87M)(7.09M)(2.72M)(144K)(579K)
Accounts Receivables(2.5M)(2.87M)302K487K277K
Inventory(3.59M)(1.59M)(1.95M)(2.67M)(2.9M)
Accounts Payables1.6M(1.55M)(987K)3.36M1.06M
Other Working Capital(1.38M)(1.07M)(91K)(1.32M)983K
Other Non-Cash Items1.01M1.66M(10.07M)6.25M7.07M
Operating Cash Flow(46.35M)(60.78M)(59.07M)(46.11M)(44.45M)
Capital Expenditures(6.92M)(10.27M)(7.31M)(3.58M)(1.8M)
Acquisitions (Net)163.96M0000
Purchases of Investments(279.96M)(366.27M)(403.09M)(272.93M)(173.17M)
Sales of Investments116M253.65M448.31M342.03M237.81M
Other Investing Activities(163.96M)170K0343K(1.3M)
Investing Cash Flow(170.88M)(122.72M)37.9M65.86M61.55M
Debt Repayment00000
Common Stock Issued102.96M000458K
Common Stock Repurchased(35K)(20K)(13K)(11.82M)(10.2M)
Dividends Paid00000
Other Financing Activities13.71M3.91M465K321K(827K)
Financing Cash Flow116.63M3.89M452K(11.5M)(10.57M)
Effect of Forex Changes00000
Net Change in Cash(100.59M)(179.61M)(20.71M)8.25M6.53M
Free Cash Flow(53.27M)(71.05M)(66.37M)(49.69M)(46.25M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.